Study Looks at Impact of FDA Safety Alert on Morcellation

This article originally appeared here.
Share this content:
Study Looks at Impact of FDA Safety Alert on Morcellation
Study Looks at Impact of FDA Safety Alert on Morcellation

FRIDAY, Jan. 22, 2016 (HealthDay News) -- The use of minimally invasive hysterectomy decreased and postoperative complications increased following the U.S. Food and Drug Administration safety communication discouraging use of laparoscopic power morcellation during hysterectomy or myomectomy for treatment of uterine fibroids, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.

John A. Harris, M.D., from the University of Michigan in Ann Arbor, and colleagues conducted a retrospective cohort study to examine temporal trends in surgical approach to hysterectomy and postoperative complications before and after the FDA safety communication. During the study period there were 18,299 hysterectomies available for analysis.

The researchers found that in the eight months after the safety communication, use of laparoscopic hysterectomies decreased by 4.1 percent (P = 0.005) and abdominal and vaginal hysterectomies increased by 1.7 and 2.4 percent, respectively (P = 0.112 and 0.012, respectively), compared with the 15 months preceding the safety communication. After the safety communication there was a significant increase in major surgical complications not including blood transfusions (P = 0.015), and the rate of hospital readmission within 30 days also increased (P = 0.025). There was no significant change in the rate of all major surgical complications or hospital reoperation after the safety communication (P = 0.177 and 0.593, respectively).

"Following the April 2014 FDA safety communication regarding power morcellation, utilization of minimally invasive hysterectomy decreased, and major surgical, nontransfusion complications and 30-day hospital readmissions increased," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths